BPC-157 10mg · Research brief

ARA 290 vs BPC 157: Mechanism and Research Evidence

Real Peptides Research TeamEditorial

Updated September 22, 20269 min read

49 WORDS

Short answer

Key takeaways

ARA-290 binds a defined target, the innate repair receptor formed by the EPO receptor and CD131, while BPC-157 has no established single receptor in the published literature.
ARA-290 is an 11-amino-acid erythropoietin-derived peptide; BPC-157 is a 15-amino-acid gastric protein fragment, so the two share no structural lineage.
ARA-290 has registered human clinical study data in small fibre neuropathy, including corneal confocal microscopy endpoints; BPC-157's evidence is overwhelmingly preclinical rodent work.
A large share of published BPC-157 research originates from a single university programme, so citation volume overstates independent replication.
Neither compound is an FDA-approved drug, and both are supplied for laboratory research use only, never for human or veterinary consumption.
Model endpoint should drive compound selection: nerve and inflammation readouts point toward ARA-290, soft-tissue and mucosal readouts toward BPC-157.

Two peptides sit under the same catalog heading, get described with the same three words, and share exactly zero receptor biology. That is the part most side-by-side write-ups skip. ARA 290 vs BPC 157 is not a contest between a stronger and a weaker version of the same idea. It is an engineered, receptor-selective fragment of a hormone on one side, and a fragment of a gastric protein with a diffuse, still-debated mechanism on the other.

We supply both compounds to laboratories, and the enquiries split cleanly. Nerve-injury and neuroinflammation groups ask about ARA-290. Tendon, ligament, and gastrointestinal mucosa groups ask about BPC-157. The overlap is much narrower than the internet chatter suggests.

What is the difference between ARA 290 and BPC 157?

ARA-290 (cibinetide) is an 11-amino-acid peptide derived from helix B of erythropoietin that binds the innate repair receptor, a heterocomplex of the EPO receptor and the beta-common receptor (CD131). BPC-157 is a 15-amino-acid sequence taken from a protein found in gastric juice, studied mainly in rodent soft-tissue and gut models. Different targets, different evidence bases.

The oversimplification worth killing early: one is for nerves, the other is for tendons. That reflects where each has been studied, not a demonstrated boundary in biology, and no adequately powered head-to-head study has compared them inside a single model. What follows covers the receptor mechanisms, why the two evidence bases are not the same size, purity and handling, and how research teams actually decide.

Two receptors with nothing in common

ARA-290 exists because researchers wanted to separate erythropoietin's tissue-protective signalling from its blood-forming signalling. Erythropoietin acts through two different receptor arrangements: the homodimeric EPO receptor on erythroid progenitor cells, which drives red cell production, and the innate repair receptor, a heterocomplex of the EPO receptor with the beta-common receptor (CD131), which is described in the literature as appearing on injured, inflamed, or hypoxic tissue. ARA-290, developed as cibinetide by Araim Pharmaceuticals, mimics the helix B surface of the parent molecule, the face that sits away from the erythropoietic binding site. Published work describes it as non-erythropoietic, meaning it does not drive the red cell pathway the way erythropoietin does.

BPC-157 has no comparably tidy story. It is a pentadecapeptide, a 15-residue partial sequence of a larger body protection compound identified in human gastric juice, and the literature has not settled on a single high-affinity receptor for it. What preclinical papers describe instead is a list of downstream effects: upregulation of VEGFR2 signalling and angiogenesis at wound sites, interaction with the nitric oxide system, and activation of the FAK-paxillin pathway in tendon fibroblast cultures. Research suggests a permissive, modulatory action rather than one clean switch.

That asymmetry is the honest starting point for ara 290 vs bpc 157. One compound has a named receptor. The other has a pathway list.

The two evidence bases are not the same size

Anyone weighing ara 290 peptide vs bpc 157 by publication count is measuring the wrong variable. ARA-290 has been through human clinical study, most visibly in sarcoidosis-associated small fibre neuropathy, with work conducted at Leiden University Medical Center that used corneal confocal microscopy to track corneal nerve fibre measures alongside patient-reported neuropathic symptom scores. Those trials were registered, monitored, and published. Neither compound is an FDA-approved drug, and ARA-290 has not completed a path to approval.

BPC-157's corpus is larger by paper count and far narrower by origin. A substantial share of it traces back to one long-running research programme led by Predrag Sikiric and colleagues at the University of Zagreb, working through rodent models of tendon transection, colitis, and related injuries across decades. The findings are internally consistent. Internal consistency is not independent replication, and citation volume badly overstates how many separate laboratories have tested the same hypothesis.

Here is the nuance almost every comparison page misses. Most rodent BPC-157 work delivered the peptide intraperitoneally or intragastrically within the animal model, so the route is baked into the reported effect. Carrying those observations across to a different route, a different species, or a different tissue compartment is an assumption, not a finding. In our experience reviewing how labs cite this material, route is the detail most often dropped from the summary.

How research teams actually choose one

Endpoint first, compound second. If the readout is small fibre density, neuropathic behaviour, neuroinflammatory markers, or ischaemic tissue protection, ARA-290 is the compound with matching literature. If the readout is tendon-to-bone healing, ligament transection recovery, or gastric and colonic mucosal integrity, BPC-157 is where the published models live. Groups interested in both generally run parallel arms rather than substituting one for the other, because the mechanisms do not converge on a shared marker.

Material quality decides whether any of that comparison survives peer review. A peptide is only the sequence the synthesis actually produced, and correct sequencing, purity, and the absence of truncated by-products separate a reproducible result from an unexplainable one. Every batch we release is small-batch synthesised with a batch certificate of analysis, which researchers can read in our published COA library before ordering ARA-290 or BPC-157. Teams building broader tissue-signalling panels often draw from the same growth factor and tissue signalling range, and an oral BPC-157 capsule format exists for models where a lyophilised vial is the wrong presentation.

Handling is unglamorous, and it is where results quietly die. Lyophilised material stays frozen; reconstituted material belongs refrigerated between 2 and 8 degrees Celsius, protected from light, and away from repeated freeze-thaw cycles that denature peptide structure invisibly. None of this is administration guidance, and any reader whose question involves an animal in their care should speak with a licensed veterinarian.

ARA 290 vs BPC 157: side-by-side research comparison

The table below lines up the attributes that change study design, not the ones that make good marketing copy. Read the final column first if you only have thirty seconds.

Comparison point	ARA-290 (cibinetide)	BPC-157	Professional assessment
Structure and origin	11-amino-acid peptide based on the helix B surface of erythropoietin	15-amino-acid pentadecapeptide, a partial sequence of a protein found in gastric juice	ARA-290 is a deliberately engineered fragment; BPC-157 is a naturally occurring fragment, which shapes how each was characterised
Receptor target	Innate repair receptor, a heterocomplex of the EPO receptor and beta-common receptor (CD131)	No single high-affinity receptor established in the published literature	A named receptor allows cleaner mechanistic experiments; BPC-157 work has to infer mechanism from downstream markers
Reported downstream pathways	Tissue-protective and anti-inflammatory signalling without stimulating the erythropoietic pathway	VEGFR2 and angiogenic signalling, nitric oxide system interaction, FAK-paxillin activation in tendon fibroblasts	BPC-157's breadth is both its appeal and its analytical weakness, since broad effects are hard to attribute
Human clinical study	Registered trials including sarcoidosis-associated small fibre neuropathy, with corneal confocal microscopy endpoints	Essentially none; the corpus is preclinical and predominantly rodent	ARA-290 carries clinical-grade endpoint data, though neither compound is an approved drug
Independence of the evidence base	Multiple investigator groups and formal trial monitoring	Heavily concentrated in one long-running university programme	Weight the BPC-157 literature by distinct research groups, not by paper count
Typical research models	Neuropathy, neuroinflammation, ischaemic and metabolic tissue injury models	Tendon and ligament transection, gastrointestinal mucosal injury, wound healing models	Choose on model fit; cross-applying either compound outside its studied models is untested territory

What If: research scenarios that change the comparison

What if a nerve model shows no signal with BPC-157?

Check whether the model's endpoint has ever been paired with BPC-157 in the literature before treating the null as a finding. Most published BPC-157 nerve work sits in peripheral injury models with specific routes and timelines, and a small fibre or central endpoint may simply fall outside the characterised range. A negative result in an unstudied model is uninformative about the compound and informative about the study design.

What if a vial arrives at ambient temperature after shipping?

Document the excursion, photograph the packaging, and contact the supplier before the material enters a study. Lyophilised peptide is comparatively tolerant of brief ambient exposure, but tolerance is not a guarantee, and denatured or partially degraded material produces variance that no downstream statistics can rescue. Batch documentation and a supplier willing to replace compromised material matter more here than unit price.

What if the design calls for both compounds in one study?

Run them as parallel arms with separate vehicle controls rather than sequentially in the same animals or cultures. Because ARA-290 acts through a defined receptor complex and BPC-157 acts through multiple angiogenic and nitric oxide-linked pathways, overlapping exposure makes attribution impossible. Comparative designs only generate usable data when each arm has its own control and a shared, pre-registered endpoint.

The unflattering truth about head-to-head peptide comparisons

Let's be direct about this: there is no published, adequately powered study that pits ara-290 vs bpc-157 in the same model with the same endpoint. Every comparison online, including this one, is an inference drawn from two separate literatures that never met. That does not make the comparison useless, but it does mean anyone claiming one compound outperforms the other is describing a preference, not a result. The defensible statement is narrower and more useful: the two have different targets, different depths of evidence, and different model histories.

What suppliers can and cannot tell you

A research supplier can verify identity, purity, and batch consistency. That is the entire honest remit. We can confirm the sequence synthesised, publish the analytical certificate for the batch in hand, and describe the storage conditions that preserve peptide structure. We cannot tell a researcher what a compound will do in their model, and we do not provide administration guidance, protocols, or human-use direction of any kind, because these are research-use-only compounds and not approved medicines.

The practical consequence for anyone weighing ara 290 vs bpc 157: judge the supplier on documentation, not on claims. A vendor that describes biological outcomes is telling you something about their marketing department. A vendor that hands over a batch certificate, states the synthesis method, and declines to speculate is telling you something about their lab. Our team has watched enough purchasing decisions go sideways to know which of those two signals actually predicts a reproducible experiment.

The comparison between ara 290 vs bpc 157 ultimately rewards researchers who ask a smaller question than the one the internet is arguing about. Not which peptide is better, but which one has been characterised in a model that resembles yours, with a mechanism specific enough to test. ARA-290 gives you a receptor to interrogate. BPC-157 gives you a wide set of downstream observations and a literature that needs more independent hands on it. Both answers are useful. Neither is a shortcut.

References

Peer-reviewed sources on BPC-157 indexed in PubMed, listed for research context. Real Peptides supplies BPC-157 for laboratory research use only.

Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS journal : the musculoskeletal journal of Hospital for Special Surgery, 2025. PMID 40756949. doi:10.1177/15563316251355551
Multifunctionality and Possible Medical Application of the BPC 157 Peptide-Literature and Patent Review. Pharmaceuticals (Basel, Switzerland), 2025. PMID 40005999. doi:10.3390/ph18020185
Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Current reviews in musculoskeletal medicine, 2025. PMID 40789979. doi:10.1007/s12178-025-09990-7
Stable Gastric Pentadecapeptide BPC 157 and Intestinal Anastomoses Therapy in Rats-A Review. Pharmaceuticals (Basel, Switzerland), 2024. PMID 39204186. doi:10.3390/ph17081081
From Regeneration to Analgesia: The Role of BPC-157 in Tissue Repair and Pain Management. International journal of molecular sciences, 2026. PMID 41898733. doi:10.3390/ijms27062876
BPC-157 and Its Novel Hybrid Analogs as Inhibitors of Acetylcholinesterase. International journal of molecular sciences, 2026. PMID 42278509. doi:10.3390/ijms27114984
Protective effects of BPC 157 in rats with experimentally induced lower extremity ischemia-reperfusion injury. Scientific reports, 2026. PMID 42204242. doi:10.1038/s41598-026-55449-1
Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study. Joint diseases and related surgery, 2026. PMID 42542926. doi:10.52312/jdrs.2026.2951

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

ARA-290 binds the innate repair receptor, a heterocomplex of the erythropoietin receptor and the beta-common receptor (CD131), which is the defined target it was engineered for. BPC-157 has no single high-affinity receptor established in the published literature; its reported activity is described through downstream pathways including VEGFR2 signalling, the nitric oxide system, and FAK-paxillin activation in tendon fibroblasts. One compound has a named receptor, the other has a pathway list.

ARA-290, under the name cibinetide, has been studied in registered human clinical trials, including work in sarcoidosis-associated small fibre neuropathy that used corneal confocal microscopy endpoints. BPC-157's published evidence is almost entirely preclinical and predominantly rodent. Neither compound is an FDA-approved drug, and both are supplied for laboratory research only.

They can, but only in a parallel-arm design with separate vehicle controls and a single pre-registered endpoint. Running them sequentially in the same animals or cultures makes attribution impossible because the mechanisms do not share a common marker. No adequately powered published head-to-head comparison currently exists, which is why most online comparisons are inferences drawn from two separate literatures.

No. Neither compound is an FDA-approved drug product for any indication. Both are sold as research-use-only materials for laboratory investigation and are never intended for human or veterinary consumption. ARA-290 has been studied in registered clinical trials but has not completed a path to approval.

Lyophilised peptide is held frozen until it is prepared for use. Once reconstituted, peptide solutions are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and away from repeated freeze-thaw cycles. Freeze-thaw damage denatures peptide structure without any visible change to the solution, which is why temperature excursions should be documented rather than assumed harmless.

A substantial share of the published BPC-157 corpus traces back to a long-running programme led by Predrag Sikiric and colleagues at the University of Zagreb, which has produced rodent injury model work over several decades. The findings are internally consistent, but internal consistency is not the same as independent replication. Anyone assessing the evidence should weight it by the number of distinct research groups rather than by total paper count.

ARA-290 is described in the literature as non-erythropoietic. It mimics the helix B surface of erythropoietin, the region that faces away from the binding site responsible for stimulating erythroid progenitor cells, and targets the innate repair receptor instead of the homodimeric EPO receptor. That separation of signalling was the design goal behind the molecule.

A useful certificate identifies the specific batch and reports identity and purity analysis for that batch, not a generic specification sheet reused across production runs. Purity, correct sequence, and the absence of truncated synthesis by-products are what determine whether an experiment is reproducible. Real Peptides publishes batch certificates in a public COA library so researchers can review documentation before purchasing.

Pricing varies by compound, vial quantity, and the level of analytical documentation supplied, so current listings on the shop page are the only accurate reference. The more meaningful cost question is what the price includes: batch-specific certificates of analysis and small-batch synthesis cost more to produce than bulk-sourced material with a generic spec sheet. Cheap peptide that fails identity testing is the most expensive option in a research budget.

Yes, BPC-157 is offered in an oral capsule presentation as well as a lyophilised vial, which suits models where a reconstituted solution is not the appropriate format. Most published rodent BPC-157 work used intraperitoneal or intragastric delivery within the animal model, so route is part of the evidence and should be matched to the source literature when designing a study.

No. These are research-use-only compounds intended for controlled laboratory investigation, not for administration to companion animals or livestock. Anyone with a question about an animal in their care should speak with a licensed veterinarian, who can assess the animal and advise on approved options.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA